ChemicalBook > Product Catalog >API >Inhibitors >Selumetinib

Selumetinib

Selumetinib Structure
CAS No.
606143-52-6
Chemical Name:
Selumetinib
Synonyms
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide;6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;113183;CS-1912;AZD 6244;AZD-6224;umetinib;Smetinib;ARRY 142886;Selumetinib
CBNumber:
CB81871940
Molecular Formula:
C17H15BrClFN4O3
Molecular Weight:
457.68
MOL File:
606143-52-6.mol
Modify Date:
2024/5/21 15:15:33

Selumetinib Properties

Melting point >219°C (dec.)
Density 1.69
storage temp. -20°
solubility Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml)
form Beige powder.
pka 14.20±0.10(Predicted)
color White
Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months.

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS05,GHS07,GHS08
Signal word  Danger
Hazard statements  H317-H318-H361d-H373
Precautionary statements  P262-P280-P312
HS Code  29349990
NFPA 704
0
3 0

Selumetinib Chemical Properties,Uses,Production

Description

Selumetinib (AZD6244; ARRY-142886) is an oral MEK inhibitor. In a randomized trial, NSCLC patients with wild-type KRAS were randomized to erlotinib alone or combination therapy with selumetinib, while mutant KRAS patients were randomized to selumetinib alone or combination therapy. The primary end points were PFS for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Results were not impressive, with no PFS difference in the KRAS wild-type arm (2.4 vs. 2.1?months) and no ORR difference in the KRASmutated subgroup (0% vs. 10%). A planned trial of selumetinib in combination with the anti-PD-L1 antibody durvalumab has since been suspended (NCT03004105).

Definition

ChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv ly. It is a MEK1 and MEK2 inhibitor.

brand name

Koselugo

General Description

Class: dual threonine/tyrosine kinase; Treatment: children with NF1; Other name: AZD-6244, ARRY-142886; Oral bioavailability = 62%; Elimination half-life = 6.2 h; Protein binding = 97.7%

Metabolism

Following oral administration of radiolabeled selumetinib, the most prominent drug-related component in the plasma was selumetinib, accounting for 40% of the plasma radioactivity. The major circulating metabolite was an amide glucuronide 2, which accounted for 22% of the plasma radioactivity. This metabolite resulted from loss of the ethanediol moiety to give the primary amide 1, which underwent glucuronidation and an additional loss of 2 mass units, most likely due to further oxidation of the N-methylbenzimidazole moiety (Fig. 5).
Figure 5. Major metabolic pathway of selumetinib in  humans.

Dosage

Selumetinib is characterized by a moderate oral bioavailability (62%) and a relatively short half-life (6.2 h), and these properties contribute to twice-daily dosing regimen (25 mg dosage).

Global( 317)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
Pharma Affiliates 172-5066494 Haryana, India 6761 58 Inquiry
Hebei Mojin Biotechnology Co., Ltd +86 13288715578 +8613288715578 China 12460 58 Inquiry
Zhengzhou Anbu Chem Co.,Ltd +86-0371-88006763; +8615988602810 China 3000 58 Inquiry
Capot Chemical Co.,Ltd. 571-85586718 +8613336195806 China 29798 60 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32760 60 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29897 58 Inquiry
Hebei Guanlang Biotechnology Co., Ltd. +86-19930503282 China 8826 58 Inquiry

Selumetinib Spectrum

ARRY 142886 AZD 6244 Selumetinib AZD624 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-car Selumetinib 5-(4-Bromo-2-chlorophenylamino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide 6-(4-Bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide SeluMatinib(5-[(4-BroMo-2-chlorophenyl)aMino]-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benziMidazole-6-carboxaMide AZD6244(SeluMetinib) AZD6244; ARRY142886 SeluMetinib (AZD6244) Array142886 AZD-6244(SeluMetinib)/AZD6244 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carbox AZD6244, ARRY-142886, ARRY-886 5-(4-BroMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benziMidazole-6-carbohydroxaMic acid 2-hydroxyethyl ester 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide Selumetinib (AZD6244) AZD 6244 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide selumetinib (MEK inhibitor) Selumetinib, >=98% AZD-6224 Selumetinib, 99%, a highly selective MEK1 inhibitor Selumetinib, Free BaseAZD6244ARRY-142886 Selumetinib (AZD6244) Selumetinib ARRY-142886; SELUMETINIB;AZD-6244;ARRY142886 AZD6244 (ARRY142886, Selumetinib) AZD6244 (Selumetinib,ARRY-142886) 113183 CS-1912 Selumetinib Base umetinib umetinib (AZD6244) SeL 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl- Selumetinib USP/EP/BP Selumetinib D4 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide 5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzodimidazol-6-carboxamide Quinoxyfen Impurity 1 Selumetinib API Smetinib 606143-52-6 60614-52-6 C17H15BrClFN4O3 MAPK Inhibitors Antineoplastic apis Aromatics Heterocycles Inhibitor Intermediates & Fine Chemicals Pharmaceuticals API Research